Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | SQLE | Q14534 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12286016 | 1.00 | KMT2A (0.48) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL119326 | 1.00 | KMT2A (0.48) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL3885097 | 0.85 | KMT2A (0.45) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL19183172 | 0.84 | KMT2A (0.41) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL5604645 | 0.83 | FNTA (0.58) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL5604622 | 0.83 | FNTA (0.58) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL14867333 | 0.83 | KMT2A (0.47) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL15129571 | 0.83 | KMT2A (0.47) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL14867372 | 0.83 | KMT2A (0.47) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL5604249 | 0.83 | FNTA (0.58) | KMT2AALOX15MEN1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559703-B2 | Fragrance composition | GIVAUDAN SA (CH) | 2026-02-24 | — | — | US | claimed |
| US-20250235136-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-07-24 | — | — | US | claimed |
| EP-4519404-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | Firmenich SA (CH) | 2025-03-12 | — | — | EP | claimed |
| CN-119403908-A | Method for enhancing psychological performance and composition for use in the method | 弗门尼舍有限公司 | 2025-02-07 | — | — | CN | claimed |
| EP-4407019-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2024-07-31 | — | — | EP | claimed |
| US-20240206778-A1 | FRAGRANCE FOR IMPROVING INVIGORATION STATE AND METHOD OF ASSESSING | GIVAUDAN SA (CH) | 2024-06-27 | — | — | US | claimed |
| WO-2023247604-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | FIRMENICH SA (CH) | 2023-12-28 | — | — | WO | claimed |
| EP-4257663-A1 | FOOD CONTACT SURFACE SANITIZING LIQUID | The Procter & Gamble Company (US) | 2023-10-11 | — | — | EP | claimed |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2023-07-27 | — | — | US | claimed |
| US-20230151305-A1 | FRAGRANCE COMPOSITION | SA, GIVAUDAN (CH) | 2023-05-18 | — | — | US | claimed |
| WO-2016049394-A1 | CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| US-20160090557-A1 | SUBSTRATES COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| US-20160089317-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| US-20160090555-A1 | CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| WO-2016049398-A1 | FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2016049396-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2016049407-A1 | ABSORBENT ARTICLE COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2016049404-A1 | SUBSTRATES COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2016049395-A1 | PRODUCTS COMPRISING MALODOR REDUCTION MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| US-20070020210-A1 | Methods of reducing the perception of body odors with olfactory adaptation and cross-adapting agents | MONELL CHEMICAL SENSES CENTER | 2007-01-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559703-B2 | Fragrance composition | DHCR24, OPRD1, OR10J3 | KMT2A 2244/4885ALOX15 40/4885MEN1 3398/4885 |
| US-20160089317-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | LPO, QDPR, TYR | KMT2A 1352/4885ALOX15 180/4885MEN1 3913/4885 |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | KMT2A 4388/4885ALOX15 514/4885MEN1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.